Registry of Patients Having Received oNKord®

NCT05290662 · tracked via the Priya Life Science Germany tracker

Sponsor

Glycostem Therapeutics BV

Phase

Observational

Started

2022-06-14

Last updated

2022-08-04

Condition(s) studied

AML

Investigational drug(s) / intervention(s)

oNKord®Cyclophosphamide/Fludarabine (Cy/Flu)

oNKord®: Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells

Cyclophosphamide/Fludarabine (Cy/Flu): Lymphodepleting conditioning regimen

Study summary

ReKORD is an observational study (Registry) enrolling participants who have received at least one dose of oNKord® (allogeneic ex vivo-generated Natural Killer \[NK\] cells from CD34+ umbilical cord blood progenitor cells) in a clinical trial. Participants from multiple previous clinical trials of oNKord® can be enrolled in this Registry.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Receipt of at least one dose of oNKord® in a clinical trial * Participation must be within 3 years after the first infusion of oNKord® * Signature of ICF Exclusion Criteria: * N/A

Primary outcome measure(s)

Incidence of SAEs related to oNKord® over time — 3 years
Safety
Incidence of SAEs related to Cyclophosphamide-Fludarabine over time — 3 years
Safety
Long-term follow-up on survival — 3 years
Long-term follow-up on disease status — 3 years
Long-term follow-up on cancer-related treatments — 3 years

Trial sites (2)

Facility	City	Region	Status
Medizinische Hochschule Hannover	Hanover	Germany	Recruiting
University Hospital Basel	Basel	Switzerland	Recruiting

Other trials for the same condition

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation Recruiting

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML Recruiting

GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05290662 on ClinicalTrials.gov ↗ ← All trials in Germany